MarketInOut Stock Screener Log In | Sign Up
 

Corvus Pharmaceuticals Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026 16:00
Corvus Pharmaceuticals Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization863.08 mln
Float64.80 mln
Earnings Date10/29/2026

Piotroski F-Score

4 / 9
Borderline

Relative Strength

66 / 100
Outperforming

Debt / Equity

0.00
Debt-free

ROE

-39.85
Deeply negative

ROA

-36.90
Deeply negative

Business Description

Corvus Pharmaceuticals is a US-based clinical-stage company focused on developing treatments that work by targeting key proteins involved in immune system function. Its pipeline includes three main drug candidates currently in clinical trials for conditions ranging from certain cancers to inflammatory and autoimmune diseases. The company supports its research through licensing partnerships with several academic and commercial organizations. Founded in 2014 and headquartered in South San Francisco, California, Corvus is working to bring forward a new generation of immune-based therapies.

Key Fundamentals

EPS-0.62
ROE-39.85
ROIC-352
ROA-36.90
Interest Cover-31.93
EBITDA, mln-54.01
EV / EBITDA-16.31
EV / EBIT-16.28

Quote Details

Last 10.53
Change -0.12 (-1.13%)
Open 10.58
Volume 933,657
Turnover 9,831,408
Average Volume 1,105,843

Financial Ratios

Leverage Ratio1.06
Current Ratio16.16
Price / Book4.31
Price / Tangible Book4.31
Debt / Equity0.00

Financial Strength

Piotroski F-Score 4 / 9
Short Ratio15.44
Short % of Float24.05

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 10.61% 95 / 100   
1 Month -10.76% 28 / 100   
2 Months -25.32% 19 / 100   
6 Months -34.51% 19 / 100   
1 Year 46.66% 91 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog